Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Biodesix (Nasdaq: BDSX) will report fourth-quarter and full-year 2025 financial results after market close on Thursday, February 26, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time the same day to review results and provide a business update.
A live webcast will be available with registration via the company’s investor site, a replay posted about two hours after the call, and participants are advised to join 15 minutes early.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
BDSX was down -0.48% while key diagnostics peers like BNR (-6.84%), PRE (-6.39%), XGN (-5.71%), MDXH (-2.2%), and FONR (-0.69%) also declined, but no peers appeared in the momentum scanner and no same-day peer news was reported.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Prelim FY2025 results | Positive | +48.0% | Preliminary Q4/FY2025 revenue above guidance and EBITDA turning positive. |
| Dec 3 | Scientific data meetings | Positive | +4.0% | New clinical and development data at NACLC and SABCS conferences. |
| Nov 3 | Q3 2025 earnings | Positive | -7.2% | Q3 revenue growth, margin expansion, and raised full‑year 2025 guidance. |
| Oct 30 | R&D roadmap event | Neutral | +0.5% | Planned R&D roadmap presentation at AMP Annual Meeting corporate day. |
| Oct 22 | Bio-Rad partnership | Positive | -12.2% | Expanded Bio-Rad partnership to develop and validate ddPCR IVD assays. |
Recent news often read positively on fundamentals or partnerships, but price reactions have been mixed, with both strong rallies and notable selloffs on seemingly positive updates.
Over the last few months, Biodesix reported strong growth and strategic progress. On Jan 12, 2026, preliminary Q4/FY2025 results showed revenue above guidance and expectations of positive Adjusted EBITDA, prompting a +47.99% move. Earlier, Q3 2025 results on Nov 3, 2025 featured 20% revenue growth and an 81% gross margin but saw a -7.17% reaction. Partnership and R&D roadmap updates in late 2025 drew modest, mixed moves. Today’s earnings-date announcement follows these preliminary numbers and formalizes when audited results will be discussed.
Market Pulse Summary
This announcement schedules the release of Biodesix’s audited Q4 and full‑year 2025 financials for February 26, 2026, with a conference call at 4:30 p.m. ET. It follows January’s preliminary results, which indicated revenue above prior guidance and an expectation of positive Adjusted EBITDA in Q4 2025. Ahead of the call, investors may focus on how final figures compare with those preliminaries and on updated commentary around margins, cash, and growth initiatives disclosed in late 2025.
AI-generated analysis. Not financial advice.
LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning possible or assumed future results of operations, including descriptions of our revenues, profitability, outlook, and overall business strategy, the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital, the anticipated impact and benefits of new clinical data, reimbursement coverage and research partnerships, the impact of enhanced U.S. tariffs, import/export restrictions or other trade barriers on the company and its operations and financial performance and management’s preliminary views regarding the company’s performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of our most recent Annual Report on Form 10-K, filed March 3, 2025, or subsequent quarterly reports on Form 10-Q during 2025, as applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey
chris.brinzey@icrhealthcare.com
(339) 970-2843
FAQ
When will Biodesix (BDSX) release its Q4 and full-year 2025 results?
What time is the Biodesix (BDSX) earnings call and webcast on February 26, 2026?
How can investors access the Biodesix (BDSX) February 26, 2026 webcast and replay?
Are analysts able to ask questions during the Biodesix (BDSX) February 26, 2026 call?
When should participants join the Biodesix (BDSX) webcast on February 26, 2026?
Will Biodesix (BDSX) provide a business update with its February 26, 2026 financial results?
